105 related articles for article (PubMed ID: 33245464)
1. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
[TBL] [Abstract][Full Text] [Related]
2. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
3. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
[TBL] [Abstract][Full Text] [Related]
4. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
[TBL] [Abstract][Full Text] [Related]
5. Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.
Limberg J; Egan CE; Gray KD; Singh M; Loewenstein Z; Yang Y; Riascos MC; Al Asadi H; Safe P; El Eshaky S; Liang H; Ullmann TM; Wang W; Li W; Zhang T; Xiang J; Stefanova D; Jin MM; Zarnegar R; Fahey TJ; Min IM
Mol Cancer Res; 2023 May; 21(5):397-410. PubMed ID: 36790391
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.
Pinto N; Prokopec SD; Ghasemi F; Meens J; Ruicci KM; Khan IM; Mundi N; Patel K; Han MW; Yoo J; Fung K; MacNeil D; Mymryk JS; Datti A; Barrett JW; Boutros PC; Ailles L; Nichols AC
PLoS One; 2020; 15(9):e0239315. PubMed ID: 32970704
[TBL] [Abstract][Full Text] [Related]
8. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
Xiong L; Lin XM; Nie JH; Ye HS; Liu J
Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
[No Abstract] [Full Text] [Related]
10. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal.
Lu Y; Zhao Y; Liu P; Xu X
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract][Full Text] [Related]
12. Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Doolittle WKL; Zhao L; Cheng SY
Thyroid; 2022 Aug; 32(8):937-948. PubMed ID: 35822558
[No Abstract] [Full Text] [Related]
13. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
Phytomedicine; 2024 Jul; 129():155670. PubMed ID: 38704915
[TBL] [Abstract][Full Text] [Related]
14. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.
Vanden Borre P; Gunda V; McFadden DG; Sadow PM; Varmeh S; Bernasconi M; Parangi S
Oncotarget; 2014 Jun; 5(12):3996-4010. PubMed ID: 24994118
[TBL] [Abstract][Full Text] [Related]
15. Disrupting glycolysis and DNA repair in anaplastic thyroid cancer with nucleus-targeting platinum nanoclusters.
Pan Z; Lu X; Hu X; Yu R; Che Y; Wang J; Xiao L; Chen J; Yi X; Tan Z; Li F; Ling D; Huang P; Ge M
J Control Release; 2024 May; 369():517-530. PubMed ID: 38569942
[TBL] [Abstract][Full Text] [Related]
16. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of vemurafenib-induced anti-tumor effects in ATC FRO cells.
Xu J; Xue D; Li Y; Zhou J; Chen H; Fan L
Heliyon; 2024 Mar; 10(6):e27629. PubMed ID: 38509927
[TBL] [Abstract][Full Text] [Related]
18. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract][Full Text] [Related]
20. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
Passaro C; Borriello F; Vastolo V; Di Somma S; Scamardella E; Gigantino V; Franco R; Marone G; Portella G
Oncotarget; 2016 Jan; 7(2):1500-15. PubMed ID: 26625205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
